

Table 18: Results of exploratory analyses ERG omalizumab

	Mepo	Omalizumab	Mepo vs. omalizumab	SoC	Mepo vs. SoC	
Scenario Number	Deterministic results incorporating scenario numbers 1-5 from Table 70					
	QALYs	██████	██████	██████	██████	
	Costs	██████	██████	██████	██████	
	ICER			Dominant	£73,573	
	Probabilistic results incorporating scenario numbers 1-5 from Table 70					
	QALYs	██████	██████	██████	██████	
	Costs	██████	██████	██████	██████	
	ICER			Dominant	£73,369	
	A	Source of annual omalizumab cost: omalizumab MTA (probabilistic)				
		QALYs	██████	██████	██████	██████
	Costs	██████	██████	██████	██████	
	ICER			Dominant	£72,965	
B	Using RRs for mOCS (probabilistic)					
	QALYs	██████	██████	██████	██████	
	Costs	██████	██████	██████	██████	
	ICER			£338,590*	£104,129	
C	Random effects model for the NMA (probabilistic)					
	QALYs	██████	██████	██████	██████	
	Costs	██████	██████	██████	██████	
	ICER			Dominant	£73,855	
	Combination of scenario numbers A-C (probabilistic): ERG base case					
	QALYs	██████	██████	██████	██████	
	Costs	██████	██████	██████	██████	
	ICER			£43,084*	£105,140	

*These ICERs lie in the South West quadrant and imply the costs saved per QALY lost with mepolizumab